Monte Rosa Therapeutics, Inc.
GLUE
$16.86
$1.459.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 181.54M | 177.99M | 159.49M | 75.62M | 14.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 181.54M | 177.99M | 159.49M | 75.62M | 14.98M |
| Cost of Revenue | 130.57M | 121.44M | 118.06M | 112.86M | 101.57M |
| Gross Profit | 50.97M | 56.55M | 41.43M | -37.24M | -86.60M |
| SG&A Expenses | 42.46M | 41.59M | 43.56M | 43.87M | 42.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 173.03M | 163.03M | 161.62M | 156.73M | 143.95M |
| Operating Income | 8.51M | 14.96M | -2.13M | -81.11M | -128.98M |
| Income Before Tax | 21.95M | 28.42M | 9.46M | -70.13M | -119.01M |
| Income Tax Expenses | 1.01M | 4.26M | 3.31M | 2.57M | 384.00K |
| Earnings from Continuing Operations | 20.95 | 24.17 | 6.15 | -72.70 | -119.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.95M | 24.17M | 6.15M | -72.70M | -119.39M |
| EBIT | 8.51M | 14.96M | -2.13M | -81.11M | -128.98M |
| EBITDA | 16.84M | 23.30M | 6.14M | -72.99M | -121.07M |
| EPS Basic | 0.26 | 0.29 | 0.02 | -1.08 | -1.83 |
| Normalized Basic EPS | 0.17 | 0.22 | 0.04 | -0.66 | -1.14 |
| EPS Diluted | 0.25 | 0.29 | 0.01 | -1.09 | -1.84 |
| Normalized Diluted EPS | 0.16 | 0.21 | 0.03 | -0.66 | -1.14 |
| Average Basic Shares Outstanding | 328.85M | 328.47M | 317.51M | 295.52M | 270.33M |
| Average Diluted Shares Outstanding | 329.66M | 329.27M | 318.32M | 295.52M | 270.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |